Prurigo nodularis (PN), one of the various subtypes of prurigo, is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intensely pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. PNs are cutaneous lesions often produced by repetitive scratching; hence the nickname “picker’s nodules”, which may occur as a sequel to chronic pruritus or neurotic excoriations. After establishing a perpetual itch-scratch cycle, lichenification of the skin may ensue, resulting in chronic dermatitis termed lichen simplex chronicus. Several lesions in different stages and sizes may co-exist in patients with chronic pruritus, which were induced by chronic scratching.
The main symptom of Prurigo Nodularis is the formation of hard, very itchy lumps (nodules) on the skin. The nodules can range in size from very small to about half an inch in diameter. The nodules often have a rough, dry top and can range in number from a few to hundreds. It is commonly found on the outer arms, shoulders, and legs. It can also appear on the neck and trunk, but rarely seen on the face and palms.
Get FREE sample copy at:
The Prurigo Nodularis market report also covers emerging drugs, current treatment practices, Prurigo Nodularis market share of the individual therapies, current and forecasted Prurigo Nodularis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Prurigo Nodularis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Prurigo Nodularis Market Key Facts
The total prevalent population of Prurigo Nodularis in the seven major markets was found to be 689,760 in 2017.
Japan accounted for the second-highest prevalent population of Prurigo Nodularis among the 7MM countries, with over 110,681 cases in 2017 that will increase by the end of 2028.
Among the European countries, Germany had the highest prevalent population of Prurigo Nodularis with 103,004 cases, followed by France with 57,996 cases in 2017. Besides, Spain had the lowest prevalent population with 44,273 cases in 2017.
As per DelveInsight’s analysis, diagnosed prevalent cases of mild, moderate, and severe Prurigo Nodularis in the US were 77,343, 62,895, and 15,299, respectively, in 2017.
Key Benefits of Prurigo Nodularis Market Report
Prurigo Nodularis market report provides an in-depth analysis of Prurigo Nodularis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Prurigo Nodularis market report will help in developing business strategies by understanding the Prurigo Nodularis Market trends & developments, key players and future market competition that will shape and drive the Prurigo Nodularis market in the upcoming years.
The Prurigo Nodularis market report covers Prurigo Nodularis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Prurigo Nodularis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Prurigo Nodularis Market
The market size of Prurigo Nodularis is expected to increase during the forecast period owing to the rise in the number of the prevalent population of Prurigo Nodularis patients in the 7MM.
The Prurigo Nodularis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Prurigo Nodularis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Prurigo Nodularis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Prurigo Nodularis Epidemiology
The Prurigo Nodularis epidemiology section covers insights about historical and current Prurigo Nodularis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Prurigo Nodularis Drugs Uptake and Key Market Players
The Prurigo Nodularis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched in the market during the study period. The analysis covers Prurigo Nodularis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The Prurigo Nodularis (PN) market size is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.
Some of the key companies in the Prurigo Nodularis market include:
Prurigo Nodularis Therapies Covered in the Report:
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Prurigo Nodularis Competitive Intelligence Analysis
4. Prurigo Nodularis Market Overview at a Glance
5. Prurigo Nodularis Disease Background and Overview
6. Prurigo Nodularis Patient Journey
7. Prurigo Nodularis Epidemiology and Patient Population
8. Prurigo Nodularis Treatment Algorithm, Current Treatment, and Medical Practices
9. Prurigo Nodularis Unmet Needs
10. Key Endpoints of Prurigo Nodularis Treatment
11. Prurigo Nodularis Marketed Products
12. Prurigo Nodularis Emerging Therapies
13. Prurigo Nodularis Seven Major Market Analysis
14. Attribute Analysis
15. Prurigo Nodularis Market Outlook (7 major markets)
16. Prurigo Nodularis Access and Reimbursement Overview
17. KOL Views on the Prurigo Nodularis Market.
18. Prurigo Nodularis Market Drivers
19. Prurigo Nodularis Market Barriers
21. DelveInsight Capabilities
Mitochondrial Myopathies Market Insight
Mitochondrial Myopathies Market Insights, Epidemiology, and Market Forecast 2030 report deliver an in-depth understanding of the Mitochondrial Myopathies historical and forecasted epidemiology as well as the Mitochondrial Myopathies market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Nephrosclerosis Market Analysis
Nephrosclerosis Market Insights, Epidemiology, and Market Forecast 2030 report deliver an in-depth understanding of the Nephrosclerosis historical and forecasted epidemiology as well as the Nephrosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States